B1 Other refereed article (e.g., editorial, letter, comment) in a scientific journal

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party




AuthorsDaenen, L. G. M.; van der Wagen, L. E.; Bonneville, E. F.; Lopez-Corral, L.; Bukauskas, A.; Bornhaeuser, M.; Beguin, Y.; Itälä-Remes, M.; Hoogenboom, J. D.; de Wreede, L. C.; Malard, F.; Chabannon, C.; Dazzi, F.; Ruggeri, A.; Kuball, J.

PublisherSpringer Science and Business Media LLC

Publishing placeLONDON

Publication year2025

JournalBone Marrow Transplantation

Journal name in sourceBone Marrow Transplantation

Journal acronymBONE MARROW TRANSPL

Volume60

First page 708

Last page714

Number of pages7

ISSN0268-3369

eISSN1476-5365

DOIhttps://doi.org/10.1038/s41409-025-02531-3

Web address https://doi.org/10.1038/s41409-025-02531-3


Abstract
Acute graft-versus-host disease (aGvHD) remains a significant complication of allogeneic hematopoietic cell transplantation, with 40% of patients failing to respond to high-dose steroids. Ruxolitinib has become the standard treatment for steroid-refractory aGvHD (SR-GvHD), but its failure in approximately one-third of cases highlights the need for alternative therapies. Mesenchymal stromal cells (MSCs), known for their immunomodulatory properties, are suggested as a treatment option, but their role in SR-GvHD remains unclear. To better understand MSC therapy outcomes, the EBMT Cellular Therapy & Immunobiology Working Party conducted a survey of centers treating >20 SR-GvHD patients with MSCs between 2007 and 2020. Data from 313 patients were analyzed, revealing a 44.5% overall response rate at day 28. Responders at day 7 had a higher likelihood of maintaining responses by day 28. Using a landmark analysis, the overall survival at 12 months, conditional on being alive at day 28, was 39.2%. Survival at 12 months was 48.6% for responders, compared to 24.4% for non-responders. Despite manufacturing variabilities, MSCs produced by academic pharma appear effective in SR-GvHD, offering a viable treatment alternative for heavily pretreated patients. These findings support further investigation of MSCs to establish standardized protocols and validate their efficacy as third-line therapy for SR-GvHD.



Last updated on 2025-21-05 at 13:23